Loading...
•
Sep 30, 2022
Intra-Cellular Q3 2022 Earnings Report
Intra-Cellular Therapies experienced strong revenue growth driven by the successful launch of CAPLYTA and investments in broadening its indications and advancing its pipeline.
Key Takeaways
Intra-Cellular Therapies reported a net loss of $53.5 million for Q3 2022. Total revenues were $71.9 million, with CAPLYTA net product revenues reaching $71.9 million, a 233% increase compared to Q3 2021. The company's cash, cash equivalents, and investment securities totaled $630.5 million.
CAPLYTA net product revenues for Q3 2022 were $71.9 million, a 233% increase year-over-year.
CAPLYTA total prescriptions increased 220% compared to the same period in 2021.
Launched two new dosage strengths of CAPLYTA, 10.5 mg and 21 mg, expanding the patient population.
Net loss for the quarter ended September 30, 2022, was $53.5 million, compared to a net loss of $76.9 million for the quarter ended September 30, 2021.
Forward Guidance
The company expects to file a supplemental New Drug Application (sNDA) with the FDA for lumateperone as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...